Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes

1. A compound of general formula (I):

wherein

R 1 is (1) halogen, (2) hydroxyl, (3) C1-4 alkyl which may be substituted with substituents selected from the group consisting of (a) —OR 7 and (b) halogen, (4) C1-4 alkoxy, or (5) C3-8 cycloalkyl;

p is an integer of 0 to 3; when p is 2 or more, each R 1 may be the same or different;

R 2 is (1) halogen, (2) oxo, (3) —OR 3 , (4) —COR 4 , (5) —COOR 5 , (6) —SO 2 R 6 , (7) C1-4 alkyl which may be substituted with substituents selected from the group consisting of (a) —OR 7 , (b) —COR 8 , (c) —COOR 9 , (d) —SO 2 R 10 , (e) halogen, and (f) cyano, (8) C3-6 monocyclic carbon ring which may be substituted with substituents selected from the group consisting of (a) C1-4 alkyl, (b) phenyl, and (c) hydroxymethyl, (9) 5 to 6 membered monocyclic hetero ring which may be substituted with substituents selected from the group consisting of (a) C1-4 alkyl, (b) phenyl, and (c) hydroxymethyl, (10) —NR 76 R 77 , (11) —CONR 78 R 79 , (12) —NR 80 COR 81 or (13) cyano;

R 3 and R 7 are independently (1) hydrogen, (2) C1-4 alkyl, (3) C1-4 haloalkyl, or (4) —COR 4 ;

R 4 and R 8 are independently C1-4 alkyl or amino;

R 5 , R 6 , R 9 and R 10 are independently hydrogen or C1-4 alkyl;

R 76 to R 81 are independently hydrogen or C1-4 alkyl;

q is an integer of 0 to 3; when q is 2 or more, more than one R 2 may be same or different;

Ring A is benzene, benzimidazole, indazole, indole, imidazole, triazole, pyrazole, pyridine, pyrimidine, thiophene, oxazole, thiazole, or oxadiazole;

Ring G is benzene;

L is (1) bond, (2) —CR 21 ═CR 22 →, (3) —X→, (4) —X—CR 23 R 24 →, (5) —CR 25 R 26 —X→, (6) —X—CR 27 R 28 —O→, (7) —X—O—CR 29 R 30 →, (8) —O—CR 31 R 32 —X→, or (9) —CR 33 R 34 —O—X→(wherein the arrow is a binding position in each group);

R 21 to R 34 are independently hydrogen or C1-4 alkyl;

X is (1) —O—, (2) —C(═O)—, (3) —NR 41 —, (4) —C(═O)—NR 42 —, or (5) —NR 43 —C(═O)—;

R 41 to R 43 are independently hydrogen or C1-4 alkyl;

M is a bond;

Z is piperidine which may be substituted with a substituent selected from the group consisting of (a) halogen, (b) —NR 53 R 54 , (c) —OR 55 , (d) C1-4 alkyl which may be substituted with —NR 56 R 57 and/or —OR 58 , and (e) oxo;

R 53 to R 58 represent independently hydrogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 acyl, —C(═O)—O—(C1-4 alkyl), —C(═O)—OCH 2 R 68 , oxetanyl, or oxolanyl;

a salt thereof, an N-oxide thereof, or a solvate thereof.

2. The compound according to claim 1 , wherein the compound is

(1) 1-{3-(3,5-dimethylphenyl)-5-[4-(trifluoromethyl)phenyl]-4-pyridinyl}-4-piperidinamine,

(2) 1-{3-(3-fluoro-5-methylphenyl)-5-[4-(trifluoromethyl)phenyl]-4-pyridinyl}-4-piperidinamine,

(3) 3-{(E)-2-[4-(4-amino-1-piperidinyl)-5-(3-fluoro-5-methylphenyl)-3-pyridinyl]vinyl}benzonitrile,

(4) 4-(4-amino-1-piperidinyl)-N,5-bis(3,5-dimethyphenyl)pyridine-3-carboxamide,

(5) 1-[3-(4,6-dimethyl-1H-benzimidazol-2-yl)-5-(3,5-dimethyphenyl)-4-pyridyl]piperidin-4-amine,

(6) 1-[3-(4,6-dimethyl-1H-benzimidazol-2-yl)-5-(3,5-dimethyphenyl)-4-pyridinyl]-N-(3-oxetanyl)-4-piperidinamine,

(7) 1-[3-(3,5-dimethoxyphenyl)-5-(5,7-dimethyl-1H-benzimidazol-2-yl)-4-pyridinyl]-N-(2-fluoroethyl)-4-piperidinamine,

(8) 1-[3-(3-fluoro-5-methoxyphenyl)-5-(1H-indazol-6-yl)-4-pyridinyl]-4-piperidinamine,

(9) 5-[4-(4-amino-1-piperidinyl)-5-(3-fluoro-5-methylphenyl)-3-pyridinyl]-2-methylphenol,

(10) 1-[3-(5-chloro-1H-benzimidazol-2-yl)-5-(3-fluoro-5-methylphenyl)-4-pyridinyl]-N-(3-oxetanyl)-4-piperidinamine,

(11) (3-{4-(4-amino-1-piperidinyl)-5-[4-(trifluoromethyl)phenyl]-3-pyridinyl}-5-fluorophenyl)methanol, or

(12) {4-[4-(4-amino-1-piperidinyl)-5-(3-fluoro-5-methylphenyl)-3-pyridinyl]phenyl} acetonitrile.

3. The compound according to claim 1 , wherein the compound is

(1) rac-(3R,4S)-4-amino-1-[3-(3,5-dimethoxyphenyl)-5-(4,6-dimethyl-1H-benzimidazol-2-yl)-4-pyridinyl]-3-piperidinol, or

(2) rac-(3R,4S)-4-amino-1-[3-(6-fluoro-1H-benzimidazol-2-yl)-5-(3-fluoro-5-methoxyphenyl)-4-pyridinyl]-3-piperidinol.

4. A pharmaceutical composition which comprises the compound of the general formula (I) according to claim 1 , a salt thereof, an N-oxide thereof, or a solvate thereof and a pharmaceutically acceptable excipient.

5. A medicine comprising the compound according to claim 1 , a salt thereof, an N-oxide thereof, or a solvate thereof and at least one drug selected from the group consisting of pegvisomant, bromocriptine, and cabergoline.

6. A medicine comprising the compound according to claim 1 , a salt thereof, an N-oxide thereof, or a solvate thereof and at least one drug selected from the group consisting of prochlorperazine, levomepromazine, risperidone, metoclopramide, domperidone, diphenhydramine, chlorpheniramine, dimenhydrinate, promethazine, diprophylline, famotidine, cimetidine, scopolamine, tropisetron, granisetron, ondansetron, azasetron, ramosetron, indisetron, palonosetron, cisapride, mosapride, dexamethasone, betamethasone, prednisolone, aprepitant, olanzapine, quetiapine, perospirone, methylnaltrexone and morphine.

7. A method for treating a somatostatin related disease, comprising administering to a mammal in need thereof an effective amount of the compound represented by the general formula (I) according to claim 1 , a salt thereof, an N-oxide thereof, or a solvate thereof, wherein the somatostatin related disease is acromegaly.